$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000110465913038837 Filed on May 08, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$3.000K	$8.000K	$2.000K
YoY Change		300.0%	-77.78%
Cost Of Revenue	$1.000K	$2.000K	$2.000K
YoY Change		0.0%	0.0%
Gross Profit	$2.000K	$6.000K	$0.00
YoY Change			-100.0%
Gross Profit Margin	66.67%	75.0%	0.0%
Selling, General & Admin	$1.560M	$1.633M	$1.762M
YoY Change	-30.08%	-7.32%	-7.02%
% of Gross Profit	78000.0%	27216.67%
Research & Development	$3.676M	$5.538M	$6.796M
YoY Change	-48.0%	-18.51%	55.44%
% of Gross Profit	183800.0%	92300.0%
Depreciation & Amortization	$130.0K	$150.0K	$179.0K
YoY Change	-18.75%	-16.2%	33.58%
% of Gross Profit	6500.0%	2500.0%
Operating Expenses	$5.236M	$7.171M	$8.558M
YoY Change	-43.7%	-16.21%	36.56%
Operating Profit	-$5.234M	-$7.165M	-$8.558M
YoY Change	-43.72%	-16.28%	36.71%
Interest Expense	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%	-99.76%
% of Operating Profit
Other Income/Expense, Net	$345.0K	$1.621M	-$897.0K
YoY Change	-82.44%	-280.71%	-170.52%
Pretax Income	-$4.890M	-$5.540M	-$9.460M
YoY Change	-33.38%	-41.44%	89.58%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.889M	-$5.544M	-$9.455M
YoY Change	-33.35%	-41.36%	89.48%
Net Earnings / Revenue	-162966.67%	-69300.0%	-472750.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.455M	-$2.473M	-$4.876M
COMMON SHARES
Basic Shares Outstanding	45.66M shares	45.66M shares	38.74M shares
Diluted Shares Outstanding			38.74M shares

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.500M	$9.200M	$36.70M
YoY Change	-84.32%	-74.93%	49.19%
Cash & Equivalents	$4.494M	$9.200M	$36.73M
Short-Term Investments
Other Short-Term Assets	$236.0K	$300.0K	$453.0K
YoY Change	-48.13%	-33.77%	13.25%
Inventory
Prepaid Expenses
Receivables			$0.00
Other Receivables			$0.00
Total Short-Term Assets	$4.730M	$9.526M	$37.20M
YoY Change	-83.76%	-74.39%	48.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$953.0K	$1.056M	$1.467M
YoY Change	-27.2%	-28.02%	22.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$953.0K	$1.056M	$1.503M
YoY Change	-27.2%	-29.74%	36.64%
TOTAL ASSETS
Total Short-Term Assets	$4.730M	$9.526M	$37.20M
Total Long-Term Assets	$953.0K	$1.056M	$1.503M
Total Assets	$5.683M	$10.58M	$38.70M
YoY Change	-81.33%	-72.66%	47.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.300M	$3.000M	$3.400M
YoY Change	-13.16%	-11.76%	47.83%
Accrued Expenses	$500.0K	$900.0K	$1.400M
YoY Change	-44.44%	-35.71%	180.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.00K	$0.00	$40.00K
YoY Change	-52.5%	-100.0%	-80.0%
Total Short-Term Liabilities	$3.842M	$4.276M	$22.35M
YoY Change	-67.96%	-80.87%	-19.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$2.000K	$29.00K
YoY Change	-100.0%	-93.1%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$2.000K	$29.00K
YoY Change	-100.0%	-93.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.842M	$4.276M	$22.35M
Total Long-Term Liabilities	$0.00	$2.000K	$29.00K
Total Liabilities	$3.842M	$4.278M	$22.38M
YoY Change	-68.01%	-80.88%	-19.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$287.0M	-$282.1M	-$251.6M
YoY Change	10.32%	12.13%
Common Stock	$246.0M	$245.6M	$229.9M
YoY Change	2.73%	6.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$41.04M	-$36.57M	-$21.72M
YoY Change
Total Liabilities & Shareholders Equity	$5.683M	$10.60M	$38.66M
YoY Change	-81.33%	-72.58%	47.57%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$4.889M	-$5.544M	-$9.455M
YoY Change	-33.35%	-41.36%	89.48%
Depreciation, Depletion And Amortization	$130.0K	$150.0K	$179.0K
YoY Change	-18.75%	-16.2%	33.58%
Cash From Operating Activities	-$4.700M	-$6.760M	-$6.600M
YoY Change	-40.88%	2.42%	2.8%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$18.00K	$82.00K
YoY Change	100.0%	-78.05%	-44.59%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities	-$20.00K	-$20.00K	-$80.00K
YoY Change	100.0%	-75.0%	-46.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$11.00K	$11.00K
YoY Change		0.0%	-82.81%
Cash From Financing Activities	-10.00K	2.370M	37.89M
YoY Change	-90.91%	-93.75%	-63250.0%
NET CHANGE
Cash From Operating Activities	-4.700M	-6.760M	-6.600M
Cash From Investing Activities	-20.00K	-20.00K	-80.00K
Cash From Financing Activities	-10.00K	2.370M	37.89M
Net Change In Cash	-4.730M	-4.410M	31.21M
YoY Change	-41.39%	-114.13%	-570.74%
FREE CASH FLOW
Cash From Operating Activities	-$4.700M	-$6.760M	-$6.600M
Capital Expenditures	-$20.00K	$18.00K	$82.00K
Free Cash Flow	-$4.680M	-$6.778M	-$6.682M
YoY Change	-41.06%	1.44%	1.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	352000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	13990000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13638000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	9526000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1188000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1056000	USD
CY2012Q4	us-gaap	Assets Assets	15178000	USD
CY2013Q1	us-gaap	Assets Assets	10582000	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3247000	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3015000	USD
CY2012Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	383000	USD
CY2013Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	858000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	34000	USD
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1995000	USD
CY2013Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	376000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5659000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4276000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6000	USD
CY2013Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	5665000	USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	41613000	USD
CY2013Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	42876000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	243215000	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	245550000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275315000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-282122000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-32100000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	-36572000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15178000	USD
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45664079	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45664000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43784000	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45664000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43784000	shares
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	8000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1906000	USD
	astm	Research And Development Agreements ResearchAndDevelopmentAgreements	2105000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	9901000	USD
CY2012Q1	us-gaap	Sales Revenue Net SalesRevenueNet	2000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	13912000	USD
CY2012Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3049000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6796000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5538000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	222268000	USD
CY2012Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1762000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	2240000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3300000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	204000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2335000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-181000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-52000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	529000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	421000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-232000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2783000	USD
CY2013Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	475000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	858000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6603000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6761000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-263378000	USD
	astm	Organizational Costs Activity OrganizationalCostsActivity	73000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	217041000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	218745000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	82000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7508000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	400000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-82000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5477000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	37723000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	89267000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2378000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	187432000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3500000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	751000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2851000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-18000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	37888000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2367000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	278081000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	31203000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1633000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	94231000	USD
CY2012Q1	us-gaap	Costs And Expenses CostsAndExpenses	8560000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	7173000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	319548000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8558000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7165000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-305636000	USD
CY2012Q1	astm	Changes In Fair Value Of Warrants ChangesInFairValueOfWarrants	-900000	USD
CY2013Q1	astm	Changes In Fair Value Of Warrants ChangesInFairValueOfWarrants	1619000	USD
	astm	Changes In Fair Value Of Warrants ChangesInFairValueOfWarrants	18156000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1249000	USD
CY2012Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10827000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	3000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	3000	USD
	us-gaap	Interest Expense InterestExpense	494000	USD
CY2012Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-897000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1621000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29738000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-9455000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-5544000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-275898000	USD
CY2012Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	289000	USD
CY2013Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	1263000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	6224000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9744000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6807000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-282122000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38742000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44864000	shares
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	179000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	150000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8297000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-110000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-1704000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	815000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	-43000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17452000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	9226000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36733000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5530000	USD
CY2013Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">2.   Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 13.5pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the three months ended March 31, 2013, are not necessarily indicative of the results to be expected for the full year or for any other period.  The December 31, 2012 condensed consolidated balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 13.5pt;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 13.5pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the period ended December 31, 2012, as filed with the SEC.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 13.5pt;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 13.5pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The consolidated financial statements include the accounts of Aastrom and its wholly-owned subsidiaries, Aastrom Biosciences GmbH, located in Berlin, Germany and Aastrom Biosciences, SL, located in Barcelona, Spain (collectively, the Company). All inter-company transactions and accounts have been eliminated in consolidation.  The subsidiaries are not a significant component of the consolidated financial statements as each has ceased operations and had limited operations historically.</font></p> </div>
CY2013Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	item
CY2013Q1	astm	Minimum Period Of Uncertainty Regarding Entitys Ability To Maintain Liquidity Sufficient To Operate Business Effectively MinimumPeriodOfUncertaintyRegardingEntitysAbilityToMaintainLiquiditySufficientToOperateBusinessEffectively	P12M
CY2013Q1	astm	Period For Which No Sufficient Cash Was Available To Sustain Operations PeriodForWhichNoSufficientCashWasAvailableToSustainOperations	P1Y
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35632110	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30565000	shares

Files In Submission

Name	View Source	Status
0001104659-13-038837-index-headers.html	Edgar Link	pending
0001104659-13-038837-index.html	Edgar Link	pending
0001104659-13-038837.txt	Edgar Link	pending
0001104659-13-038837-xbrl.zip	Edgar Link	pending
a13-8573_110q.htm	Edgar Link	pending
a13-8573_1ex31d1.htm	Edgar Link	pending
a13-8573_1ex31d2.htm	Edgar Link	pending
a13-8573_1ex32d1.htm	Edgar Link	pending
astm-20130331.xml	Edgar Link	completed
astm-20130331.xsd	Edgar Link	pending
astm-20130331_cal.xml	Edgar Link	unprocessable
astm-20130331_def.xml	Edgar Link	unprocessable
astm-20130331_lab.xml	Edgar Link	unprocessable
astm-20130331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2013 Q2 Form 10-Q Financial Statement

#000110465913038837 Filed on May 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2013 Q2 Form 10-Q Financial Statement

#000110465913038837 Filed on May 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel